



Trajectory of Growth of SARS-CoV-2 Variants in Houston, Texas, January through May 2021 Based on 12,476 Genome Sequences

Randall J. Olsen, Paul A. Christensen, S. Wesley Long, Sishir Subedi, Parsa Hodjat, Robert Olson, Marcus Nguyen, James J. Davis, Prasanti Yerramilli, Matthew Ojeda Saavedra, Layne Pruitt, Kristina Reppond, Madison N. Shyer, Jessica Cambric, Ryan Gadd, Rashi M. Thakur, Akanksha Batajoo, Ilya J. Finkelstein, Jimmy Gollihar, James M. Musser

PII: S0002-9440(21)00317-5

DOI: <https://doi.org/10.1016/j.ajpath.2021.07.002>

Reference: AJPA 3610

To appear in: *The American Journal of Pathology*

Received Date: 11 June 2021

Revised Date: 30 June 2021

Accepted Date: 2 July 2021

Please cite this article as: Olsen RJ, Christensen PA, Long SW, Subedi S, Hodjat P, Olson R, Nguyen M, Davis JJ, Yerramilli P, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd R, Thakur RM, Batajoo A, Finkelstein IJ, Gollihar J, Musser JM, Trajectory of Growth of SARS-CoV-2 Variants in Houston, Texas, January through May 2021 Based on 12,476 Genome Sequences, *The American Journal of Pathology* (2021), doi: <https://doi.org/10.1016/j.ajpath.2021.07.002>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2021 Published by Elsevier Inc. on behalf of the American Society for Investigative Pathology.

Trajectory of Growth of SARS-CoV-2 Variants in Houston, Texas, January through May 2021 Based on 12,476 Genome Sequences

Randall J. Olsen,^{*,†,‡} Paul A. Christensen,^{*,†} S. Wesley Long,^{*,†,‡} Sishir Subedi,^{*,†} Parsa Hodjat,[†]
Robert Olson,^{§,¶} Marcus Nguyen,^{§,¶} James J. Davis,^{§,¶} Prasanti Yerramilli,[†] Matthew Ojeda
Saavedra,[†] Layne Pruitt,[†] Kristina Reppond,[†] Madison N. Shyer,[†] Jessica Cambric,[†] Ryan Gadd,[†]
Rashi M. Thakur,[†] Akanksha Batajoo,[†] Ilya J. Finkelstein,[#] Jimmy Gollihar,^{†,**} and
James M. Musser^{†,‡,††}

^{*}*Contributed equally;*

[†]*Center for Molecular and Translational Human Infectious Diseases Research, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, 6565 Fannin Street, Houston, Texas, 77030;*

[‡]*Departments of Pathology and Laboratory Medicine, and Microbiology and Immunology, Weill Cornell Medical College, 1300 York Avenue, New York, New York, 10065;*

[§]*Consortium for Advanced Science and Engineering, 22 University of Chicago, 5801 South Ellis Avenue, Chicago, Illinois, 60637;*

[¶]*Computing, Environment and Life Sciences, Argonne National Laboratory, 9700 South Cass Avenue, Lemont, Illinois, 60439;*

[#]*Department of Molecular Biosciences and Institute of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712;*

^{*f}*CCDC Army Research Laboratory-South, University of Texas, Austin, Texas 78712*

^{††}Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street, Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail: jmmusser@houstonmethodist.org

Running head: SARS-CoV-2 genomic variants in Houston

Disclosures: None.

Number of text pages: 22

Number of tables: 2

Number of figures: 8

Funding: This project was supported by the Houston Methodist Academic Institute Infectious Diseases Fund; and supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076 (J.J.D. and R.O.).

Abstract

Certain genetic variants of SARS-CoV-2 are of substantial concern because they may be more transmissible or detrimentally alter the pandemic course and disease features in individual patients. We report SARS-CoV-2 genome sequences from 12,476 patients in the Houston Methodist healthcare system diagnosed from January 1 through May 31, 2021. Prevalence of the B.1.1.7 (Alpha) variant increased rapidly and caused 63%-90% of new cases in the latter half of May. Eleven B.1.1.7 genomes had an E484K replacement in spike protein, a change also identified in other SARS-CoV-2 lineages. Compared with non-B.1.1.7-infected patients, individuals with B.1.1.7 had a significantly lower cycle threshold (a proxy for higher virus load) and significantly higher hospitalization rate. Other variants (e.g., B.1.429 and B.1.427 (Epsilon), P.1 (Gamma), P.2 (Zeta), and R.1) also increased rapidly, although the magnitude was less than B.1.1.7. We identified 22 patients infected with B.1.617.1 (Kappa) or B.1.617.2 (Delta) variants; these patients had a high rate of hospitalization. Breakthrough cases ($n=207$) in fully vaccinated patients were caused by a heterogeneous array of virus genotypes, including many that are not currently designated variants of interest or concern. In the aggregate, our study delineates the trajectory of SARS-CoV-2 variants circulating in a major metropolitan area, documents B.1.1.7 as the major cause of new cases in Houston, and heralds the arrival of B.1.617 variants in the metroplex.

[Introduction]

The global pandemic caused by SARS-CoV-2 that began in early 2020 has been challenging for every academic health center and health system, hospital, and public health system in the United States and countries worldwide.¹⁻⁷ The pandemic has also provided unprecedented opportunities for basic and translational research in all biomedical fields. We have systematically analyzed the molecular population genomics of SARS-CoV-2 in the ethnically and socioeconomically diverse metropolitan Houston area (population 7 million) since the first COVID-19 cases were reported in very early March 2020.⁸⁻¹¹ Our studies are facilitated by a central molecular diagnostic laboratory that comprehensively identifies and retains all COVID-19 diagnostic specimens from our large healthcare system that includes eight hospitals, emergency care clinics, and outpatient centers distributed throughout the metropolitan region. In addition, we have leveraged our longstanding interest in pathogen genomics and sequencing infrastructure to investigate the spread of SARS-CoV-2 in metropolitan Houston.⁸⁻¹⁶ Among other discoveries, we have reported that the SARS-CoV-2 viruses causing infections in the earliest phase of the pandemic affecting Houston had substantial genomic diversity and are progeny of strains derived from several continents, including Europe and Asia.^{8,9} These findings indicated that SARS-CoV-2 was introduced into our region many times independently by individuals who had traveled from different parts of the country and the world. Subsequently, sequence analysis of 5,085 genomes causing the first disease wave and massive second disease wave in Houston showed that all strains in the second wave had an D614G amino acid replacement in the spike protein.⁹ The D614G polymorphism increases human transmission and infectivity *in vitro* and *in vivo* in

animal infection models.¹⁷⁻²² Importantly, this was the first study to analyze the molecular architecture of SARS-CoV-2 in two infection waves in any major metropolitan region.

One of our key goals since the start of the pandemic has been to sequence all positive SARS-CoV-2 specimens from patients in our hospital system and rapidly identify mutations that may be associated with detrimental patient outcome, including therapeutic or vaccine failure. Similarly, with the recognition of an increasing number of SARS-CoV-2 variants of interest (VOIs) and variants of concern (VOCs) by public health agencies such as the United States Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and Public Health England (PHE) (<https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html>, last accessed: June 8, 2021; <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed: June 8, 2021), there is now substantial domestic and international need to identify these virus genotypes rapidly and understand their velocity and patterns of dissemination. In particular, VOC B.1.1.7 (also termed Alpha), first identified in the UK, is of special interest because it has the ability to transmit very effectively, spread through populations rapidly, and has been reported to have a significantly higher mortality rate than non-B.1.1.7 infections (<https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563>, last accessed: June 8, 2021, https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/947048/Technical_Briefing_VOC_SH_NJL2_SH2.pdf, last accessed: June 8, 2021, <https://app.box.com/s/3lkcbxepqixkg4mv640dpvvg978ixjtf/file/756963730457>, last accessed: June 8, 2021, <https://cmmid.github.io/topics/covid19/uk-novel-variant.html>, last accessed: June 8, 2021,

[english-national-lockdown/575](#), last accessed: June 8, 2021).²³⁻³⁷ VOCs B.1.351 (Beta) and P.1 (Gamma), found to cause widespread disease in South Africa and Brazil, respectively, have sequence changes in spike protein that make them less susceptible to host, and some therapeutic antibodies.³⁸⁻⁴¹ Recently, two additional VOIs, B.1.427 and B.1.429 (Epsilon), were recognized by the CDC in part because of their rapid transmission in many California communities⁴² (<https://outbreak.info/situation-reports?pango=B.1.427>, last accessed June 8, 2021, <https://outbreak.info/situation-reports?pango=B.1.429>, last accessed June 8, 2021).

Based on sequencing 20,453 SARS-CoV-2 genomes causing COVID-19 disease in Houston, we recently reported that all named VOIs and VOCs are circulating in the metropolitan region, making it the first community to document their presence.¹⁰ A follow-up study reported rapid increase of VOC U.K. B.1.1.7 in Houston¹¹; we estimated the cases infected with the variant had a doubling time of approximately 7 d. This rapid B.1.1.7 growth trajectory raised the possibility that this variant would cause nearly all new COVID-19 cases in metropolitan Houston by the end of March or early April 2021, a time frame similar to an estimate made in late January by the CDC.³⁴

Here we report integrated virus genome and patient data for 12,476 unique COVID-19 cases identified between January 1, 2021 and May 31, 2021, including 3,276 patients with the B.1.1.7 VOC. We find that in the latter half of May, depending on the day, 63%-90% of all new COVID-19 cases in metropolitan Houston were caused by B.1.1.7. Linked medical record information available for virtually all sequenced genomes permitted us to study the relationship between virus genotypes and patient phenotypes. Patients infected with B.1.1.7 had significantly lower cycle threshold values in nasopharyngeal specimens (considered to be a proxy for higher virus load) and a significantly higher hospitalization rate compared with non-B.1.1.7 patients.

There was no difference between these two groups in hospital length of stay or mortality. Eleven of the 3,276 B.1.1.7 genomes (0.3%) had an E484K change in spike protein that reduces binding by some neutralizing antibodies. Unexpectedly, we found five cases of B.1.1.7 from samples collected in early December, resulting in a revised time frame for the introduction of this variant to Houston. We also identified 22 patients with COVID-19 caused by B.1.617.1 (Kappa) or B.1.617.2 (Delta) variants reported to be causing widespread disease and extensive public health problems in India, other Southeast Asian countries, and many regions of the UK (<https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---8-june-2021>, last accessed June 9, 2021).⁴³⁻⁵⁰ These patients also had a high rate of hospitalization. Vaccine breakthrough cases ($n = 207$) were caused by diverse virus genotypes, many of which were not VOCs or VOIs. Our genome data show that VOCs and VOIs now account for the great majority of all new COVID-19 cases in our region, identify B.1.1.7 as the major cause of new cases in Houston, and document the arrival and spread of B.1.617 variants in the Houston metroplex.

Materials and Methods

Patient Specimens

Specimens were obtained from registered patients at Houston Methodist hospitals, associated facilities (e.g., urgent care centers), and institutions in the Houston metropolitan region that use

our laboratory services. Virtually all individuals had signs or symptoms consistent with COVID-19 disease. We analyzed a comprehensive sample of genomes obtained from January 1, 2021 through May 31, 2021. This time frame was chosen for convenience because it represents the period during which, at the onset of the study, we identified an uptick in identification of VOIs and VOCs. The study included all 12,476 unique patients identified in this time frame. The work was approved by the Houston Methodist Research Institute Institutional Review Board (IRB1010-0199).

SARS-CoV-2 Molecular Diagnostic Testing

Specimens obtained from symptomatic patients with a suspicion for COVID-19 disease were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital using assays granted Emergency Use Authorization (EUA) from the FDA (<https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2#offeringtests>, last accessed June 7, 2021). As a hedge against supply chain strictures, multiple molecular testing platforms were used, including the COVID-19 test or RP2.1 test with BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the cobas SARS-CoV-2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay using the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system, and the SARS-CoV-2 assay using Abbott Alinity m instruments. The great majority of tests were performed on material obtained from nasopharyngeal swabs immersed in universal transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar

lavage fluid, or sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen collection methods were used (<https://vimeo.com/396996468/2228335d56>, last accessed June 7, 2021).

SARS-CoV-2 Genome Sequencing

Libraries for whole virus genome sequencing were prepared according to version 3 of the ARTIC nCoV-2019 sequencing protocol (<https://artic.network/ncov-2019>, last accessed June 7, 2021). We used a semi-automated workflow that employed BioMek i7 liquid handling workstations (Beckman Coulter Life Sciences) and MANTIS automated liquid handlers (FORMULATRIX). Short sequence reads were generated with a NovaSeq 6000 instrument (Illumina). For continuity of the epidemiologic analysis in the study period, we included some genome sequences reported in a recent publication.¹⁰

SARS-CoV-2 Genome Sequence Analysis and Identification of Variants

Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service (<https://www.bv-brc.org/app/ComprehensiveSARS2Analysis>, last accessed June 7, 2021, requires registration). The One Codex SARS-CoV-2 variant calling and consensus assembly pipeline was used to assemble all sequences (<https://github.com/onecodex/sars-cov-2.git>, last accessed June 7, 2021) using default parameters and a minimum read depth of 3. Briefly, the pipeline uses seqtk version 1.3-r116 for sequence trimming (<https://github.com/lh3/seqtk.git>, last accessed June 7, 2021); minimap version 2.1 for aligning reads against reference genome

Wuhan-Hu-1 (NC_045512.2); samtools version 1.11 for sequence and file manipulation; and iVar version 1.2.2 for primer trimming and variant calling. Genetic lineages, VOCs, and VOIs were identified based on genome sequence data and designated by Pangolin v. 3.0.5 with pangoLEARN module 2021-06-05 (<https://cov-lineages.org/pangolin.html>, last accessed June 7, 2021).

Patient Metadata and Geospatial Analysis

Patient metadata (**Table 1 and Table 2**) were acquired from the electronic medical record by standard informatics methods. Patient home address zip codes were used to visualize the geospatial distribution of spread for each VOC and VOI. Figures were generated with Tableau version 2020.3.4 ([Tableau Software, LLC, Seattle, WA](#)). A vaccination breakthrough case was defined as a PCR-positive sample from a symptomatic patient obtained greater than 14 days after full vaccination (i.e., both doses of the Pfizer or Moderna mRNA vaccines) was completed.

Results

Epidemiologic Trajectory and Patient Overview

Metropolitan Houston has experienced three distinct epidemiologic peaks of COVID-19 (**Figure 1**). The timing and shape of the epidemiologic curve for Houston Methodist patients mirrors the

curve for the metropolitan region (<https://covid-harriscounty.hub.arcgis.com/pages/cumulative-data>, last accessed June 7, 2021). The third wave of COVID-19 started in approximately early November, following a prolonged disease trough occurring after the second wave (**Figure 1**). We studied 12,476 patients from January 1, 2021 through May 31, 2021, a period during which most of the VOIs and VOCs were initially identified in Houston, and several of them increased substantially (**Table 1, Figures 2, 3 and 4**).

The median age of the patients studied was 52.5 years, and 53% were female; 6,033 (48.4%) patients required hospitalization. The ethnic distribution of the patients (**Table 1**) broadly reflects metropolitan Houston, which has a majority-minority population composition. Median length of stay was (5.2 days), and the 28-day mortality rate was 4.7%.

Occurrence of VOIs and VOCs

The CDC has identified nine VOIs (B.1.427 and B.1.429 (Epsilon), B.1.525 (also termed Eta), B.1.526 and B.1.526.1 (Iota), P.2 (Zeta), B.1.617, B.1.617.1 (Kappa), and B.1.617.3) and four VOCs (B.1.1.7 (Alpha), B.1.617.2 (Delta), P.1 (Gamma), B.1.351 (Beta)) based on heightened concern about potential or proven threat to public health and individual patients. The following VOI were identified in our comprehensive sample of 12,476 genome sequences: B.1.427 ($n = 58$), B.1.429 ($n = 293$), B.1.525 ($n = 26$), B.1.526 ($n = 39$), B.1.526.1 ($n = 9$), B.1.617.1 ($n = 5$), and P.2 ($n = 74$). All four VOCs were found, including B.1.1.7 ($n = 3,276$), P.1 ($n = 87$), B.1.617.2 ($n = 17$), B.1.351 ($n = 4$), (**Figures 2, 3 and 4, Figure 5**). B.1.1.7 rapidly increased in the population and now dominates the new-infection landscape in Houston (**Figures 2, 3 and 4**). In the last half of May, depending on the specific day, the B.1.1.7 variant caused 63%-90% of

new COVID-19 cases. In addition, we found that cases caused by variants P.1, P.2, B.1.429, and the B.1.617 family also increased during the study period, although not to the magnitude of B.1.1.7 infections (**Figures 2, 3 and 4**).

Variants Genetically Related to B.1.617

Although comprehensive data are not available from India, the B.1.617, B.1.617.1, B.1.617.2, and B.1.617.3 variants were recently described as causing widespread COVID-19 disease in that country⁴³⁻⁴⁵ (<https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---11-may-2021>, last accessed May 16, 2021) and have been designated as VOIs or VOCs by the CDC. B.1.617-family variants also have been reported to be prominent causes of new COVID-19 cases in other countries in Southeast Asia and the United Kingdom (<https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---8-june-2021>, last accessed June 9, 2021).⁴³⁻⁵⁰ Variant B.1.617 is resistant to the monoclonal antibody Bamlanivimab (LY-Cov555), as assessed by an *in vitro* host-cell entry assay,⁴⁶ and B.1.617.1 has been reported to be highly virulent in hamsters following intranasal inoculation.⁴⁵ These two variants are characterized by a core group of amino acid replacements in spike protein: L452R, T478K or E484Q, D614G, and P681R (**Figure 6**). Importantly, genetic variation exists among sequences classified as B.1.617.1 and B.1.617.2. Among these 5 B.1.617.1 and 17 B.1.617.2 variant samples, we identified four and 11 distinct subvariants, respectively (**Figure 6**). Two of the patients with B.1.617.1 and three of the patients with B.1.617.2 had a recent travel history to a high-prevalence country. One additional B.1.617.2 patient had a history of recent international travel to an unspecified country. Examination of the metadata available for patients with B.1.617

variants found that relative to non-B.1.617 patients, a higher percentage of cases were of Asian ethnicity, and a lower percentage of patients were Hispanic or Latino (**Table 2**). In addition, B.1.617 patients had a higher hospitalization rate than non-B.1.617 patients (**Table 2**).

Cycle Threshold (Ct) Value Comparison of B.1.1.7 and Non-B.1.1.7 Samples

Early in the pandemic, it was reported that nasopharyngeal samples from patients infected with strains having the spike protein D614G variant have, on average, significantly lower Ct values (considered to be a proxy for higher virus loads) on initial diagnosis^{9,17}. Most authorities think that higher virus load in the upper respiratory tract is related to enhanced ability to spread and infect others, although there are many factors that contribute to virus transmission and disease. We first tested the hypothesis that specimens from patients with B.1.1.7 infections had lower Ct values compared to non-B.1.1.7 patients based on data generated by the Abbott Alinity m or Hologic Panther molecular diagnostic assays. Consistent with the hypothesis, patient samples with the B.1.1.7 variant had significantly lower mean Ct value (**Table 1 and Figure 7**) on these instruments, and thus likely have higher nasopharyngeal virus loads. We next tested the hypothesis that other VOCs and VOIs have significantly lower Ct values. For this analysis, we removed B.1.1.7 samples because their inclusion would confound the data. The data show that B.1.427/9 samples also had significantly lower Ct values; further analysis found that this signal was attributable to the results for the B.1.429 samples (**Figure 7**). Ct data for the P.2 and R.1 patient samples were also significantly lower (**Figure 7**). Taken together, these observations are consistent with the idea that, on average, several common SARS-CoV-2 variants have significantly lower Ct values, a feature that may make them better able to disseminate and

become dominant variants in the population. The sample sizes for the other VOCs and VOIs are not adequate to analyze meaningfully.

Variant Geospatial Distribution

We next examined the geospatial distribution of all VOCs and VOIs in metropolitan Houston. With the exception of the B.1.351, B.1.526.1, B.1.617.1, and B.1.617.2 variants (due to small sample sizes), patients infected with all other variants were dispersed broadly throughout metropolitan Houston, a finding consistent with the propensity of SARS-CoV-2 to spread rapidly between individuals (**Figures 2, 3 and 4**).

E484 Spike Protein Amino Acid Changes and Convergent Evolution

Amino acid replacements at position E484 in spike protein have been of considerable research and public health interest, in part because they can decrease the efficacy of SARS-CoV-2 therapeutic antibodies and vaccine- or infection-induced adaptive immunity. We identified 363 samples with changes at E484 (E484K, $n = 353$; E484Q, $n = 9$; and E484D, $n = 1$) that occurred in many genetically diverse SARS-CoV-2 lineages, some of which have not shared a recent common ancestor. For example, we found the E484K polymorphism in samples from 69 patients infected with VOI P.2 and 43 patients infected with the newly described variant R.1.⁵¹⁻⁵³ R.1 has the following core spike protein amino acid changes: W152L, E484K, D614G, and G769V (<https://outbreak.info/situation-reports?pango=R.1>, last accessed May 17, 2021). Some R.1 variants we identified also contain R21T, L54F, S254P, or P1162L changes. Of note, we

identified 11 patients infected with B.1.1.7 plus the E484K amino acid change, and one patient each infected with B.1.1.7 sample plus either an E484Q or an E484D amino acid change. E484K replacement alters the immunologic profile of SARS-CoV-2,^{39, 40, 54-56} and Greaney et al.⁵⁷ reported that E484Q reduced viral neutralization for some plasma samples.

N440K Spike Protein Replacement

The N440K amino acid change in spike protein has recently been of interest because samples with this polymorphism have been reported to cause widespread COVID-19 in some states in India, increase viral titer *in vitro*, and have been associated with resistance to some candidate monoclonal antibody therapies.^{58, 59} We identified 18 patients with this N440K replacement, and ten patients had the identical combination of spike amino acid replacements: L18R, T95I, R158S, N440K, D614G, P681H, A688V, S735A, and T1027I. Two additional patients had SARS-CoV-2 of this same spike protein genotype with an additional T376I amino acid replacement. Pangolin categorized these strains as B.1. These 18 individuals were from 14 different zip codes dispersed throughout five counties in metropolitan Houston (data not shown). Ten of the 18 patients required hospitalization, and all were subsequently discharged.

Unexpected Identification of Samples with the B.1.1.7 Variant in Early December 2020

In work conducted contemporaneously with the present study, we have routinely sequenced all genomes from earlier in the pandemic in Houston, including the uptick part of the third wave of

disease occurring in November and December 2020 (**Figure 1**). We identified five patients in the first ten days of December with infections caused by B.1.1.7, an unexpected result because the first Houston Methodist patient previously documented with this VOC was identified in early January 2021,¹⁰ and the first Texas patient with B.1.1.7 was announced by state public health authorities on January 7, 2021 (<https://www.dshs.texas.gov/news/releases/2021/20210107a.aspx>, last accessed May 17, 2021). Thus, our genome data revise these timelines. Based on genome sequences deposited in GISAID (www.gisaid.org, last accessed May 17, 2021), only five B.1.1.7 sequences from the United States were deposited with collection dates before these five Houston B.1.1.7 patients tested positive. Thus, these Houston patients are some of the earliest documented infections caused by the B.1.1.7 VOC in the U.S., a finding that further highlights the importance of comprehensive genome sequencing of large populations from metropolitan areas with diverse patient populations.

Variants and Vaccine Breakthrough COVID-19 Cases

COVID-19 vaccines have remarkably high efficacy in preventing clinical infection caused by SARS-CoV-2, as shown by large randomized-controlled trials.⁶⁰⁻⁶² Two mRNA-based vaccines given Emergency Use Authorization by the Food and Drug Administration have been used widely in the United States (<https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine>, last accessed May 28, 2021, <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine>, last accessed May 28, 2021), and extensively in the Houston Methodist health system. Despite the very high efficacy of these two mRNA-based

vaccines, a relatively small percentage of individuals who have received all recommended doses have developed either asymptomatic or symptomatic SARS-CoV-2 infections.⁶³⁻⁶⁵ The contributors to vaccine breakthroughs are not fully understood, but there is concern that genetic variants of SARS-CoV-2 may play an outsized role, especially those with structural changes in spike protein that can alter immunologic characteristics. Consistent with this idea, McEwen et al.⁶⁵ recently reported that all 20 vaccine breakthrough cases identified at the University of Washington were caused by VOCs. In contrast, a nationwide study found that 64% of breakthrough cases were caused by VOCs, although genome data were available from only 5% of reported cases included in the study⁶⁴.

To test the hypothesis that VOCs and VOIs were overrepresented among post-vaccination breakthrough infections among our COVID-19 cases, we examined metadata available for the 12,476 patients reported here. We identified 224 patients who met the criteria of vaccine breakthrough (i.e., infection occurring greater than 14 days after full vaccination was completed). SARS-CoV-2 genome sequence data were obtained for 207 cases (**Table 1**). Of these 207 patients, 72 (34.8%) required hospitalization. The 207 patients were infected with a heterogeneous array of variants, only some of which were VOIs or VOCs (**Figure 8**). In the aggregate, there was a significant increase in VOIs or VOCs among the breakthrough cases ($p < 0.001$) (**Table 1**). Importantly, the infecting viruses generally reflected the spectrum of SARS-CoV-2 variants circulating in the Houston metropolitan region during the time of diagnosis of the vaccine breakthrough case. For example, in January and February 2021 many diverse variants were causing disease in the metroplex, and reflecting that fact, the viruses causing breakthrough cases were genetically heterogeneous (**Figure 8**). Similarly, as the B.1.1.7 VOC rose to prominence in Houston in March, April, and May, it caused the great majority of vaccine

breakthrough cases (**Figure 8**). Of note, five breakthrough cases in April and May were caused by VOC P.1; this variant was also increasing in disease frequency during this period (**Figures 2, 3 and 4**).

Discussion

We analyzed the molecular population genomics of SARS-CoV-2 occurring in metropolitan Houston, Texas, with a focus on infections occurring early in 2021, from January 1 through May 31. Our study was based on genome sequences from 12,476 ethnically, socioeconomically, and geographically diverse patients distributed throughout the metropolitan area. We discovered that infections caused by B.1.1.7 increased very rapidly, and in the latter half of May caused 63%-90% of all new cases in the population. Compared with non-B.1.1.7 patients, individuals infected with B.1.1.7 had significantly lower virus Ct values and a higher rate of hospitalization, but no difference in length of stay or mortality. We also identified 22 patients infected with B.1.617-family variants, genotypes that are now causing extensive disease in India, elsewhere in Southeast Asia, and several areas of the U.K.⁴³⁻⁴⁵

A key finding from our study was the very rapid growth trajectory of VOC B.1.1.7 in metropolitan Houston, an area with a population size of approximately 7 million. Several investigators have reported previously that patients infected with the B.1.1.7 VOC have significantly lower Ct values on initial diagnosis, but this has not been a universal finding.^{11, 66-71} In the absence of quantitative virus cultures, the Ct value is viewed by many as a convenient proxy for virus load. We found a significantly decreased Ct value in nasopharyngeal swabs taken

from B.1.1.7 patients compared to non-B.1.1.7 patients (**Table 1, Figure 7**), a result consistent with previous reports.^{11, 67, 72-74} Thus, our data are consistent with the potential for enhanced transmissibility of B.1.1.7 due to higher nasopharyngeal virus loads. However, it is clear that there is no uniform relationship between Ct value and ability to disseminate. For example, we identified patients infected with B.1.1.7 who had high Ct values and non-B.1.1.7 patients with low Ct values. Many factors contribute to SARS-CoV-2 transmission dynamics, including but not limited to, behavioral characteristics of human populations, percentage of susceptible individuals, vaccination status, network structure, and biologic variation in the capacity of virus genotypes to survive and be successfully transmitted. Collectively, our findings stress the need for more information about the relationship between Ct values, quantitative virus cultures, and specific genotypes of SARS-CoV-2.

We identified a significantly increased hospitalization rate for patients with B.1.1.7 compared to non-B.1.1.7 patients, but no significant difference in length of hospitalization or 28-day mortality (**Table 1**). Several studies have examined the relationship between disease severity and B.1.1.7.²³⁻³⁷ Patone et al.³⁶ estimated the risk of critical care admission and overall mortality associated with B.1.1.7 compared to the original variant circulating in the U.K. among a very large group of patients. They reported that patients infected with B.1.1.7 have significantly increased risk for critical care admission and mortality compared to patients not infected with B.1.1.7. However, the risk of mortality was linked to receiving critical care, not distinct virus genotype. They concluded that VOC B.1.1.7 causes more severe disease.

In the U.K., at the end of February, the B.1.1.7 variant accounted for 98% of all COVID-19 cases (https://en.wikipedia.org/wiki/Lineage_B.1.1.7, last accessed June 9, 2021).²⁷ A similar rapid increase in B.1.1.7 its population dominance has been reported in many countries,

including Israel, France, Denmark, Norway, Lebanon, and Norway

(https://en.wikipedia.org/wiki/Lineage_B.1.1.7, last accessed June 9, 2021). Our data show that this variant increased rapidly in metropolitan Houston since January 2021, and in the second half of May caused 63%-90% of new COVID-19 cases daily. However, the increase in B.1.1.7 as percent of new cases has occurred in the context of a substantial decrease in total COVID-19 cases in our metropolitan region (**Figure 1**). Although the precise cause of these seemingly disparate trends is unknown, we hypothesize that a relatively successful early vaccination campaign in the region coupled with heightened public awareness and concern about variants contributed to the decreasing case rate, whereas the increase in percent of cases caused by B.1.1.7 is attributed to the capacity of this variant to transmit more rapidly than other variants. We cannot rule out a contribution of a small but significant ability of B.1.1.7 to evade immunity induced by either natural infection or vaccination, and our data are fully consistent with this idea (**Table 1**). In this regard, data have been published showing that B.1.1.7 differs in some immunologic characteristics compared to “wild-type” SARS-CoV-2.⁷⁵⁻⁸²

SARS-CoV-2 variants with the E484K amino acid replacement are of particular concern in many areas, including Brazil, South Africa, and India (<https://www.cidrap.umn.edu/news-perspective/2021/02/pfizer-moderna-vaccines-may-be-less-effective-against-b1351-variant>, last accessed: May 17, 2021). Consistent with other studies, we identified the E484K change in several genetically distinct lineages of the virus, a finding likely due to convergent evolution, as noted previously by others.^{39, 40, 54-56, 83} In the UK, genome sequencing efforts have identified the E484K change in some B.1.1.7 samples, although it remains a minor subpopulation (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959426/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5.pdf, last accessed May

17, 2021).⁸⁴ The B.1.1.7 plus E484K variant has been reported very infrequently elsewhere in the U.S. (<https://outbreak.info/situation-reports?pango=B.1.1.7&mut=S%3AE484K>, last accessed May 17, 2021). Our data mirror the U.K. findings and other U.S. findings in that we identified this amino acid change in only 11 (0.3%) of the 3,276 B.1.1.7 patients.

The R.1 variant was first reported in Arizona in October 2020, and soon thereafter was identified in Canada and Japan (<https://outbreak.info/situation-reports?pango=R.1>, last accessed May 17, 2021).⁵¹⁻⁵³ Cavanaugh et al.⁵¹ recently reported that an R.1 lineage variant was responsible for a COVID-19 outbreak in a skilled nursing facility in Kentucky in March 2021. The first Houston Methodist patient with the variant R.1 was identified in mid-December 2020, and its prevalence increased during the study period (**Figures 2, 3 and 4**). Interestingly, for unknown reasons, its prevalence plateaued by early April (**Figures 2, 3 and 4**).

We studied 207 symptomatic patients documented to be fully immunized and who had a specimen taken for diagnosis greater than 14 days after receiving their second dose of either the Pfizer ($n = 181$ patients, 87%) or Moderna ($n = 26$ patients, 13%) mRNA SARS-CoV-2 vaccine. Because we are sequencing the virus genomes causing the vast majority of Houston Methodist Hospital cases (93%), we discovered that these vaccine breakthrough cases were caused by many diverse SARS-CoV-2 genotypes, including VOIs, VOCs, and many variants not assigned to either of these categories (**Figure 8**). Our results are similar to those reported by Birhane et al.⁶⁴ but contrast with those reported recently by McEwen et al.⁶⁵ who found that all 20 breakthrough cases were caused by VOCs. Although we found the B.1.1.7 VOC caused most of the breakthrough cases from mid-April onward, this prominence reflected the rapid increase and abundance of this variant throughout the Houston area during that period. Clearly, more

understanding is needed of the factors underlying vaccine breakthrough infections, and studies are underway to examine potential contributors.

Although extensive genomic data are not available, members of the B.1.617 variant family are contributing to the COVID-19 disease surge in India and other countries in Southeast Asia (<https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---8-june-2021>, last accessed June 9, 2021).⁴³⁻⁵⁰ B.1.617 variants also have been documented to be increasing rapidly in many areas of the U.K., and have been estimated to be 60% more transmissible than B.1.1.7, the variant that rapidly rose to dominate new infections in the U.K.^{49, 50, 85} In this regard, the identification of 22 patients in the Houston metropolitan area infected with variants B.1.617.1 and B.1.617.2 is concerning. One of the 22 Houston patients was diagnosed in mid-March 2021, which makes it one of the earliest documented cases of this variant in the U.S., with only 11 cases identified prior to this, starting on February 25th (www.gisaid.org, last accessed: May 17, 2021). The relatively high number of B.1.617 subvariants ($n = 14$) was unexpected (**Table 2, Figure 6**), and likely reflects the very large population size of B.1.617-family variants worldwide. In this regard, we note that several of our patients recently traveled outside the U.S. The B.1.617-family variants have amino acid changes in spike protein (**Figure 6**) that have been linked to increased transmissibility and resistance to antibodies that are generated by natural infection or vaccination, and altered virulence in some studies.^{43-45, 47, 48} It will be important to continue to monitor SARS-CoV-2 genomes from patients in the Houston area to determine the rate of spread of the variants, and assess if new variants that arise have biomedically relevant phenotypes, such as enhanced virulence and immunologic escape.

Limitations

Our study has several limitations. During the January 1 through May 31, 2021 study period, 269,341 cases of COVID-19 were reported in Harris County and its eight contiguous counties (https://usafactsstatic.blob.core.windows.net/public/data/covid-19/covid_confirmed_usafacts.csv; last accessed June 8, 2021). Thus, although we have sequenced 93% of all Houston Methodist cases identified during this period, our genome sample represents only 4.6% of all reported cases in the metropolitan region. Our eight hospitals and outpatient clinics are geographic widely dispersed across the metropolitan region and serve patients who are demographically, socioeconomically, and geographically highly diverse. However, unless all SARS-CoV-2 genotypes are equally distributed throughout all populations in the Houston metropolitan region, our sample may underrepresent some SARS-CoV-2 genotypes causing COVID-19 in some populations such as the homeless and other disenfranchised individuals. Our hospitals and clinics care mainly for adult patients, which means that SARS-CoV-2 variants causing pediatric cases are underrepresented in our study, although overall, the number of cases in this age group is relatively small. Finally, virtually all SARS-CoV-2 genomes that we sequenced were obtained from symptomatic patients, which may reflect the 48.4% overall hospitalization rate. Thus, our sample may underrepresent genotypes causing only asymptomatic carriage.

Summary

To summarize, in the latter half of May 2021, 63%-90% of all new COVID-19 cases among ethnically, geographically, and socioeconomically diverse Houston Methodist health care system patients were caused by the B.1.1.7 variant. Vaccine breakthrough cases were caused by SARS-CoV-2 that are genetically very diverse and largely reflect the genotypes that are circulating and abundant in the community. Identification of 22 patients with the B.1.617 family of variants and 11 patients with B.1.1.7 plus E484K in metropolitan Houston is cause for heightened concern.

Although our sample represents only 4.6% of all reported COVID-19 cases in the Houston area, it is reasonable to extrapolate that B.1.617-family variants have caused approximately 400 cases in our region. The rate and extent of spread of these variants should be monitored very closely by rapid genome sequencing, coupled with analysis of patient metadata, including disease severity and mortality. This is an especially pressing issue for B.1.617-family variants because B.1.617.2 has become abundant and is outcompeting B.1.1.7 in many areas of the U.K.

(<https://outbreak.info/location-reports?loc=GBR>, last accessed June 8, 2021,

<https://www.telegraph.co.uk/global-health/science-and-disease/indian-variant-covid-coronavirus-uk/>, last accessed June 8, 2021). Moreover, our data show a high rate of hospitalization for

patients infected with B.1.617 variants (**Table 2**), a finding consistent with data recently reported by Public Health England (<https://www.gov.uk/government/news/confirmed-cases-of-covid-19-variants-identified-in-uk>, last accessed June 9, 2021).

Acknowledgments

We thank the many talented and dedicated molecular technologists, and volunteers in the Molecular Diagnostics Laboratory and Methodist Research Institute for their dedicated efforts. We are indebted to Drs. Marc Boom and Dirk Sostman for their support, to generous Houston philanthropists for their support and to the Houston Methodist Academic Institute Infectious Diseases Fund that have made this ongoing project possible. James J. Davis and Robert Olson were funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076. We thank Jessica W. Podnar and personnel in the University of Texas Genome Sequencing and Analysis Facility for sequencing some of the genomes in this study. We thank Trina Trinh, Hung-Che Kuo and G. Nguyen for genome sequencing support. We gratefully acknowledge the originating and submitting laboratories of the SARS-CoV-2 genome sequences from GISAID's EpiFlu Database used in some of the work presented here. We also thank many colleagues for critical reading of the manuscript and suggesting improvements, and Dr. Sasha Pejerrey, Dr. Kathryn Stockbauer, Adrienne Winston, and Dr. Heather McConnell for help with figures, tables, and editorial contributions.

Author Contributions

J.M.M. conceptualized and designed the project; R.J.O., P.A.C., S.W.L., S.S., R.O., M.N., J.J.D., P.Y., M.O.S., L.P., K.R., M.N.S., R.G., J.C., R.M.T., A.B., I.J.F., and J.G. performed research. All authors contributed to writing the manuscript.

References

- [1] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020, 395:497-506.
- [2] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus I, Research T: A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020, 382:727-33.
- [3] Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet* 2020, 395:514-23.
- [4] Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ: A new coronavirus associated with human respiratory disease in China. *Nature* 2020, 579:265-9.
- [5] Coronaviridae Study Group of the International Committee on Taxonomy of V: The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol* 2020, 5:536-44.
- [6] Wang C, Horby PW, Hayden FG, Gao GF: A novel coronavirus outbreak of global health concern. *Lancet* 2020, 395:470-3.
- [7] Allel K, Tapia-Munoz T, Morris W: Country-level factors associated with the early spread of COVID-19 cases at 5, 10 and 15 days since the onset. *Glob Public Health* 2020, 15:1589-602.
- [8] Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JR, Shukla M, Nguyen M, Ojeda Saavedra M, Cantu CC, Yerramilli P, Pruitt L, Subedi S, Hendrickson H, Eskandari G, Kumaraswami M, McLellan JS, Musser JM: Molecular Architecture of Early Dissemination and Evolution of the SARS-CoV-2 Virus in Metropolitan Houston, Texas. *bioRxiv* 2020:2020.05.01.072652. <http://dx.doi.org/10.1101/2020.05.01.072652>
- [9] Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, Nguyen M, Saavedra MO, Yerramilli P, Pruitt L, Subedi S, Kuo HC, Hendrickson H, Eskandari G, Nguyen HAT, Long JH, Kumaraswami M, Goike J, Boutz D, Gollihar J, McLellan JS, Chou CW, Javanmardi K, Finkelstein IJ, Musser JM: Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. *MBio* 2020, 11:e02707-20.
- [10] Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, Saavedra MO, Yerramilli P, Pruitt L, Reppond K, Shyer MN, Cambric J, Finkelstein IJ, Gollihar J, Musser JM: Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern. *Am J Pathol* 2021, 191:983-92.
- [11] Musser JM, Olsen RJ, Christensen PA, Long SW, Subedi S, Davis JJ, Gollihar J: Rapid, widespread, and preferential increase of SARS-CoV-2 B.1.1.7 variant in Houston, TX, revealed by 8,857 genome sequences. *medRxiv* 2021:2021.03.16.21253753. <http://dx.doi.org/10.1101/2021.03.16.21253753>
- [12] Long SW, Olsen RJ, Eagar TN, Beres SB, Zhao P, Davis JJ, Brettin T, Xia F, Musser JM: Population Genomic Analysis of 1,777 Extended-Spectrum Beta-Lactamase-Producing

Klebsiella pneumoniae Isolates, Houston, Texas: Unexpected Abundance of Clonal Group 307. MBio 2017, 8.

[13] Long SW, Beres SB, Olsen RJ, Musser JM: Absence of patient-to-patient intrahospital transmission of *Staphylococcus aureus* as determined by whole-genome sequencing. MBio 2014, 5:e01692-14.

[14] Wright AM, Beres SB, Consamus EN, Long SW, Flores AR, Barrios R, Richter GS, Oh SY, Garufi G, Maier H, Drews AL, Stockbauer KE, Cernoch P, Schneewind O, Olsen RJ, Musser JM: Rapidly progressive, fatal, inhalation anthrax-like infection in a human: case report, pathogen genome sequencing, pathology, and coordinated response. Arch Pathol Lab Med 2011, 135:1447-59.

[15] Nasser W, Beres SB, Olsen RJ, Dean MA, Rice KA, Long SW, Kristinsson KG, Gottfredsson M, Vuopio J, Raisanen K, Caugant DA, Steinbakk M, Low DE, McGeer A, Darenberg J, Henriques-Normark B, Van Beneden CA, Hoffmann S, Musser JM: Evolutionary pathway to increased virulence and epidemic group A *Streptococcus* disease derived from 3,615 genome sequences. Proc Natl Acad Sci U S A 2014, 111:E1768-76.

[16] Kachroo P, Eraso JM, Beres SB, Olsen RJ, Zhu L, Nasser W, Bernard PE, Cantu CC, Saavedra MO, Arredondo MJ, Strobe B, Do H, Kumaraswami M, Vuopio J, Grondahl-Yli-Hannuksela K, Kristinsson KG, Gottfredsson M, Pesonen M, Pensar J, Davenport ER, Clark AG, Corander J, Caugant DA, Gaini S, Magnussen MD, Kubiak SL, Nguyen HAT, Long SW, Porter AR, DeLeo FR, Musser JM: Integrated analysis of population genomics, transcriptomics and virulence provides novel insights into *Streptococcus pyogenes* pathogenesis. Nat Genet 2019, 51:548-59.

[17] Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI, Sheffield C-GG, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC, Saphire EO, Montefiori DC: Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell 2020, 182:812-27 e19.

[18] Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, Zhang X, Muruato AE, Zou J, Fontes-Garfias CR, Mirchandani D, Scharton D, Bilello JP, Ku Z, An Z, Kalveram B, Freiberg AN, Menachery VD, Xie X, Plante KS, Weaver SC, Shi PY: Spike mutation D614G alters SARS-CoV-2 fitness. Nature 2021, 592:116-21.

[19] Daniloski Z, Jordan TX, Ilmain JK, Guo X, Bhabha G, tenOever BR, Sanjana NE: The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. Elife 2021, 10.

[20] Zhang L, Jackson CB, Mou H, Ojha A, Peng H, Quinlan BD, Rangarajan ES, Pan A, Vanderheiden A, Suthar MS, Li W, Izard T, Rader C, Farzan M, Choe H: SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun 2020, 11:6013.

[21] Volz E, Hill V, McCrone JT, Price A, Jorgensen D, O'Toole A, Southgate J, Johnson R, Jackson B, Nascimento FF, Rey SM, Nicholls SM, Colquhoun RM, da Silva Filipe A, Shepherd J, Pascall DJ, Shah R, Jesudason N, Li K, Jarrett R, Pacchiarini N, Bull M, Geidelberg L, Siveroni I, Consortium C-U, Goodfellow I, Loman NJ, Pybus OG, Robertson DL, Thomson EC, Rambaut A, Connor TR: Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell 2021, 184:64-75 e11.

- [22] Benton DJ, Wrobel AG, Roustan C, Borg A, Xu P, Martin SR, Rosenthal PB, Skehel JJ, Gamblin SJ: The effect of the D614G substitution on the structure of the spike glycoprotein of SARS-CoV-2. *Proc Natl Acad Sci U S A* 2021, 118.
- [23] Grubaugh ND, Hodcroft EB, Fauver JR, Phelan AL, Cevik M: Public health actions to control new SARS-CoV-2 variants. *Cell* 2021, 184:1127-32.
- [24] Walensky RP, Walke HT, Fauci AS: SARS-CoV-2 Variants of Concern in the United States-Challenges and Opportunities. *JAMA* 2021, 325:1037-8.
- [25] Mascola JR, Graham BS, Fauci AS: SARS-CoV-2 Viral Variants-Tackling a Moving Target. *JAMA* 2021, 325:1261-2.
- [26] Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW, Tully DC, Washburne AD, Wenseleers T, Gimma A, Waite W, Wong KLM, van Zandvoort K, Silverman JD, Group CC-W, Consortium C-GU, Diaz-Ordaz K, Keogh R, Eggo RM, Funk S, Jit M, Atkins KE, Edmunds WJ: Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* 2021, 372:2020.12.24.20248822.
- [27] Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW, Tully DC, Washburne AD, Wenseleers T, Gimma A, Waite W, Wong KLM, van Zandvoort K, Silverman JD, Group CC-W, Consortium C-GU, Diaz-Ordaz K, Keogh R, Eggo RM, Funk S, Jit M, Atkins KE, Edmunds WJ: Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* 2021, 372.
- [28] Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera G, O'Toole A, Amato R, Ragonnet-Cronin M, Harrison I, Jackson B, Ariani CV, Boyd O, Loman NJ, McCrone JT, Gonçalves S, Jorgensen D, Myers R, Hill V, Jackson DK, Gaythorpe K, Groves N, Sillitoe J, Kwiatkowski DP, Flaxman S, Ratmann O, Bhatt S, Hopkins S, Gandy A, Rambaut A, Ferguson NM: Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. *medRxiv* 2021:2020.12.30.20249034. <http://dx.doi.org/10.1101/2020.12.30.20249034>
- [29] Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, Kläser K, Canas LS, Molteni E, Modat M, Drew DA, Nguyen LH, Polidori L, Selvachandran S, Hu C, Capdevila J, Hammers A, Chan AT, Wolf J, Spector TD, Steves CJ, Ourselin S: Changes in symptomatology, re-infection and transmissibility associated with SARS-CoV-2 variant B.1.1.7: an ecological study. *medRxiv* 2021:2021.01.28.21250680. <http://dx.doi.org/10.1101/2021.01.28.21250680>
- [30] Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L: Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ* 2021, 372:n579.
- [31] Lumley SF, Rodger G, Constantinides B, Sanderson N, Chau KK, Street TL, O'Donnell D, Howarth A, Hatch SB, Marsden BD, Cox S, James T, Warren F, Peck LJ, Ritter TG, de Toledo Z, Warren L, Axten D, Cornall RJ, Jones EY, Stuart DI, Sreaton G, Ebner D, Hoosdally S, Chand M, Crook DW, O'Donnell A-M, Conlon CP, Pouwels KB, Walker AS, Peto TEA, Hopkins S, Walker TM, Stoesser NE, Matthews PC, Jeffery K, Eyre DW: An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status. *medRxiv* 2021:2021.03.09.21253218. <http://dx.doi.org/10.1101/2021.03.09.21253218>
- [32] Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ET, Schiabor Barrett KM, Larsen BB, Anderson C, White S, Cassens T, Jacobs S, Levan G, Nguyen J, Ramirez JM, 3rd, Rivera-Garcia C, Sandoval E, Wang X, Wong D, Spencer E, Robles-Sikisaka R, Kurzban E, Hughes LD, Deng X, Wang C, Servellita V, Valentine H, De Hoff P, Seaver P, Sathe S, Gietzen

- K, Sickler B, Antico J, Hoon K, Liu J, Harding A, Bakhtar O, Basler T, Austin B, MacCannell D, Isaksson M, Febbo PG, Becker D, Laurent M, McDonald E, Yeo GW, Knight R, Laurent LC, de Feo E, Worobey M, Chiu CY, Suchard MA, Lu JT, Lee W, Andersen KG: Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. *Cell* 2021, 184:2587-94 e7.
- [33] Stephen M. Kissler JRF, Christina Mack, Caroline G. Tai, Mallery I., Breban AEW, Radhika M. Samant, Deverick J. Anderson, David D. Ho, Nathan, D. Grubaugh YHG: Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2. DASH Preprint.
- [34] Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, Slayton RB, Tong S, Silk BJ, Armstrong GL, Biggerstaff M, Dugan VG: Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. *MMWR Morb Mortal Wkly Rep* 2021, 70:95-9.
- [35] Alpert T, Lasek-Nesselquist E, Brito AF, Valesano AL, Rothman J, MacKay MJ, Petrone ME, Breban MI, Watkins AE, Vogels CBF, Russell A, Kelly JP, Shudt M, Plitnick J, Schneider E, Fitzsimmons WJ, Khullar G, Metti J, Dudley JT, Nash M, Wang J, Liu C, Hui P, Muyombwe A, Downing R, Razeq J, Bart SM, Murphy S, Neal C, Laszlo E, Landry ML, Cook PW, Fauver JR, Mason CE, Luring AS, St George K, MacCannell DR, Grubaugh ND: Early introductions and community transmission of SARS-CoV-2 variant B.1.1.7 in the United States. *medRxiv* 2021:2021.02.10.21251540. <http://dx.doi.org/10.1101/2021.02.10.21251540>
- [36] Patone M, Thomas K, Hatch R, Tan PS, Coupland C, Liao W, Mouncey P, Harrison D, Rowan K, Horby P, Watkinson P, Hippisley-Cox J: Analysis of severe outcomes associated with the SARS-CoV-2 Variant of Concern 202012/01 in England using ICNARC Case Mix Programme and QResearch databases. *medRxiv* 2021:2021.03.11.21253364. <http://dx.doi.org/10.1101/2021.03.11.21253364>
- [37] Piantham C, Ito K: Estimating the increased transmissibility of the B.1.1.7 strain over previously circulating strains in England using frequencies of GISAID sequences and the distribution of serial intervals. *medRxiv* 2021:2021.03.17.21253775. <http://dx.doi.org/10.1101/2021.03.17.21253775>
- [38] Naveca F, Nascimento V, Souza V, Corado A, Nascimento F, Silva G, Costa Á, Duarte D, Pessoa K, Gonçalves L, Brandão MJ, Jesus M, Fernandes C, Pinto R, Silva M, Mattos T, Wallau GL, Siqueira MM, Resende PC, Delatorre E, Gräf T, Bello G: Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein. *virological.org* 2021.
- [39] Voloch CM, Silva F Rd, de Almeida LGP, Cardoso CC, Brustolini OJ, Gerber AL, Guimarães APdC, Mariani D, Costa RMd, Ferreira OC, Cavalcanti AC, Frauches TS, de Mello CMB, Galliez RM, Faffe DS, Castiñeiras TMPP, Tanuri A, de Vasconcelos ATR: Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. *medRxiv* 2020:2020.12.23.20248598. <http://dx.doi.org/10.1101/2020.12.23.20248598>
- [40] Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N, Mlisana K, von Gottberg A, Walaza S, Allam M, Ismail A, Mohale T, Glass AJ, Engelbrecht S, Van Zyl G, Preiser W, Petruccione F, Sigal A, Hardie D, Marais G, Hsiao M, Korsman S, Davies M-A, Tyers L, Mudau I, York D, Maslo C, Goedhals D, Abrahams S, Laguda-Akingba O, Alisoltani-Dehkordi A, Godzik A, Wibmer CK, Sewell BT, Lourenço J, Alcantara LCJ, Pond SLK, Weaver S, Martin D, Lessells RJ, Bhiman JN, Williamson C, de Oliveira T: Emergence and rapid spread of a new severe acute respiratory syndrome-related

coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv 2020:2020.12.21.20248640. <http://dx.doi.org/10.1101/2020.12.21.20248640>

[41] Bobeil SM, Janowska K, McDowell S, Mansouri K, Parks R, Stalls V, Kopp M, Manne K, Li D, Wiehe K, Saunders K, Edwards R, Korber B, Haynes B, Henderson R, Acharya P: Effect of natural mutations of SARS-CoV-2 on spike structure, conformation and antigenicity. *Science* 2021, Jun 24:eabi6226.

[42] Zhang W, Davis BD, Chen SS, Sincuir Martinez JM, Plummer JT, Vail E: Emergence of a Novel SARS-CoV-2 Variant in Southern California. *JAMA* 2021, 325:1324-6.

[43] Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, Rakshit P, Singh S, Abraham P, Panda S: Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. *bioRxiv* 2021:2021.04.22.440932.

<http://dx.doi.org/10.1101/2021.04.22.440932>

[44] Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, Nyayanit DA, Gupta N, Sahay RR, Shete AM, Panda S, Bhargava B, Mohan VK: Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. *Clin Infect Dis* 2021:2021.04.23.441101.

[45] Yadav PD, Mohandas S, Shete AM, Nyayanit DA, Gupta N, Patil DY, Sapkal GN, Potdar V, Kadam M, Kumar A, Kumar S, Suryavanshi D, Mote CS, Abraham P, Panda S, Bhargava B: SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant. *bioRxiv* 2021:2021.05.05.442760. <http://dx.doi.org/10.1101/2021.05.05.442760>

[46] Hoffmann M, Hofmann-Winkler H, Krüger N, Kempf A, Nehlmeier I, Graichen L, Sidarovich A, Moldenhauer A-S, Winkler MS, Schulz S, Jäck H-M, Stankov MV, Behrens GMN, Pöhlmann S: SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. *bioRxiv* 2021:2021.05.04.442663.

<http://dx.doi.org/10.1101/2021.05.04.442663>

[47] Ferreira I, Datir R, Kemp S, Papa G, Rakshit P, Singh S, Meng B, Pandey R, Ponnusamy K, Radhakrishnan VS, Sato K, James L, Agrawal A, Gupta RK: SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies. *bioRxiv* 2021:2021.05.08.443253.

<http://dx.doi.org/10.1101/2021.05.08.443253>

[48] Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-Gonzalez A, Glasner DR, Reyes KR, Gliwa AS, Reddy NP, Sanchez San Martin C, Federman S, Cheng J, Balcerak J, Taylor J, Streithorst JA, Miller S, Sreekumar B, Chen PY, Schulze-Gahmen U, Taha TY, Hayashi JM, Simoneau CR, Kumar GR, McMahon S, Lidsky PV, Xiao Y, Hemarajata P, Green NM, Espinosa A, Kath C, Haw M, Bell J, Hacker JK, Hanson C, Wadford DA, Anaya C, Ferguson D, Frankino PA, Shivram H, Lareau LF, Wyman SK, Ott M, Andino R, Chiu CY: Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. *Cell* 2021.

[49] Challen R, Dyson L, Overton CE, Guzman-Rincon LM, Hill EM, Stage HB, Brooks-Pollock E, Pellis L, Scarabel F, Pascall DJ, Blomquist P, Tildesley M, Williamson D, Siebert S, Xiong X, Youngman B, Read JM, Gog JR, Keeling MJ, Danon L: Early epidemiological signatures of novel SARS-CoV-2 variants: establishment of B.1.617.2 in England. *medRxiv* 2021. <http://dx.doi.org/10.1101/2021.06.05.21258365>

[50] Vöhringer HS, Sanderson T, Sinnott M, De Maio N, Nguyen T, Goater R, Schwach F, Harrison I, Hellewell J, Ariani C, Gonçalves S, Jackson D, Johnston I, Jung AW, Saint C, Sillitoe J, Suci M, Goldman N, Birney E, Funk S, Volz E, Kwiatkowski D, Chand M, Martincorena I, Barrett JC, Gerstung M: Genomic reconstruction of the SARS-CoV-2 epidemic

across England from September 2020 to May 2021. medRxiv 2021.

<http://dx.doi.org/10.1101/2021.05.22.21257633>

[51] Cavanaugh AM, Fortier S, Lewis P, Arora V, Johnson M, George K, Tobias J, Lunn S, Miller T, Thoroughman D, Spicer KB: COVID-19 Outbreak Associated with a SARS-CoV-2 R.1 Lineage Variant in a Skilled Nursing Facility After Vaccination Program - Kentucky, March 2021. *MMWR Morb Mortal Wkly Rep* 2021, 70:639-43.

[52] Hirotsu Y, Omata M: Household transmission of SARS-CoV-2 R.1 lineage with spike E484K mutation in Japan. medRxiv 2021. <http://dx.doi.org/10.1101/2021.03.16.21253248>

[53] Tokumasu R, Weeraratne D, Snowdon J, Parida L, Kudo M, Koyama T: Introductions and evolutions of SARS-CoV-2 strains in Japan. medRxiv 2021.

<http://dx.doi.org/10.1101/2021.02.26.21252555>

[54] Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Liebeskind MJ, Alford B, Buchser WJ, Ellebedy AH, Fremont DH, Diamond MS, Whelan SPJ: Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. *Cell host & microbe* 2021, 29:477-88 e4.

[55] Liu H, Wei P, Zhang Q, Chen Z, Aviszus K, Downing W, Peterson S, Reynoso L, Downey GP, Frankel SK, Kappler J, Marrack P, Zhang G: 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to Bamlanivimab in vitro. bioRxiv 2021.

<http://dx.doi.org/10.1101/2021.02.16.431305>

[56] Zhou D, Dejnirattisai W, Supasa P, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Tuekprakhon A, Nutalai R, Wang B, Paesen GC, Lopez-Camacho C, Slon-Campos J, Hallis B, Coombes N, Bewley K, Charlton S, Walter TS, Skelly D, Lumley SF, Dold C, Levin R, Dong T, Pollard AJ, Knight JC, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M, Belij-Rammerstorfer S, Gilbert S, James W, Carroll MW, Klennerman P, Barnes E, Dunachie SJ, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR: Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* 2021, 184:2348-61 e6.

[57] Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD: Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. *Cell host & microbe* 2021, 29:463-76 e6.

[58] Tandel D, Gupta D, Sah V, Harinivas Harshan K: N440K variant of SARS-CoV-2 has Higher Infectious Fitness. bioRxiv 2021:2021.04.30.441434.

<http://dx.doi.org/10.1101/2021.04.30.441434>

[59] Rani PR, Imran M, Lakshmi JV, Jolly B, Jain A, Surekha A, Senthivel V, Chandrasekhar P, Divakar MK, Srinivasulu D, Bhoyar RC, Vanaja PR, Scaria V, Sivasubbu S: Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape. *J Med Virol* 2021, 93:4163-5.

[60] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Jr., Hammitt LL, Tureci O, Nell H, Schaefer A, Unal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC, Group CCT: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020, 383:2603-15.

[61] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Roupheal N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S,

Ivarsson M, Miller J, Zaks T, Group CS: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021, 384:403-16.

[62] Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* 2021.

[63] Hacısuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F, Gaebler C, Lifton R, Nussenzweig MC, Hatzioannou T, Bieniasz PD, Darnell RB: Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N Engl J Med* 2021.

[64] Team CC-VBCI: COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. *MMWR Morb Mortal Wkly Rep* 2021, 70:792-3.

[65] McEwen AE, Cohen S, Bryson-Cahn C, Liu C, Pergam SA, Lynch J, Schippers A, Strand K, Whimbey E, Mani NS, Zelikoff AJ, Makarewicz VA, Brown ER, Mohamed Bakhash SA, Baker NR, Castor J, Livingston RJ, Huang M-L, Jerome KR, Greninger AL, Roychoudhury P: Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State. *medRxiv* 2021:2021.05.23.21257679. <http://dx.doi.org/10.1101/2021.05.23.21257679>

[66] Falush D, Wirth T, Linz B, Pritchard JK, Stephens M, Kidd M, Blaser MJ, Graham DY, Vacher S, Perez-Perez GI, Yamaoka Y, Megraud F, Otto K, Reichard U, Katzowitsch E, Wang X, Achtman M, Suerbaum S: Traces of human migrations in *Helicobacter pylori* populations. *Science* 2003, 299:1582-5.

[67] Golubchik T, Lythgoe KA, Hall M, Ferretti L, Fryer HR, MacIntyre-Cockett G, de Cesare M, Trebes A, Piazza P, Buck D, Todd JA, Fraser C, Bonsall D: Early analysis of a potential link between viral load and the N501Y mutation in the SARS-COV-2 spike protein. *medRxiv* 2021:2021.01.12.20249080. <http://dx.doi.org/10.1101/2021.01.12.20249080>

[68] Walker AS, Vihta K-D, Gethings O, Pritchard E, Jones J, House T, Bell I, Bell JI, Newton JN, Farrar J, Diamond I, Studley R, Rourke E, Hay J, Hopkins S, Crook D, Peto T, Matthews PC, Eyre DW, Stoesser N, Pouwels KB: Increased infections, but not viral burden, with a new SARS-CoV-2 variant. *medRxiv* 2021:2021.01.13.21249721. <http://dx.doi.org/10.1101/2021.01.13.21249721>

[69] Alizon S, Selinger C, Sofonea MT, Haim-Boukobza S, Giannoli J-M, Ninove L, Pillet S, Vincent T, de Rougemont A, Tumiotto C, Solis M, Stephan R, Bressollette-Bodin C, Salmona M, L'Honneur A-S, Behillil S, Lefeuvre C, Dina J, Hantz S, Hartard C, Veyer D, Delagrèverie HM, Fourati S, Visseaux B, Henquell C, Lina B, Foulongne V, Burrel S: Epidemiological and clinical insights from SARS-CoV-2 RT-PCR cycle amplification values. *medRxiv* 2021:2021.03.15.21253653. <http://dx.doi.org/10.1101/2021.03.15.21253653>

[70] Hay JA, Kennedy-Shaffer L, Kanjilal S, Lennon NJ, Gabriel SB, Lipsitch M, Mina MJ: Estimating epidemiologic dynamics from cross-sectional viral load distributions. *medRxiv* 2021:2020.10.08.20204222. <http://dx.doi.org/10.1101/2020.10.08.20204222>

[71] Ratcliff J, Nguyen D, Fish M, Rhyne J, Jennings A, Williams S, Al-Beidh F, Bonsall D, Evans A, Golubchik T, Gordon AC, Lamikanra A, Tsang P, Ciccone N, Leuschner U, Slack W, Laing E, Mouncey PR, Ziyenge S, Olivera M, Ploeg R, Rowan KM, Shankar-Hari M, Roberts DJ, Menon DK, Estcourt L, Simmonds P, Harvala H: Virological and serological

- characterization of critically ill patients with COVID-19 in the UK: a special focus on variant detection. medRxiv 2021:2021.02.24.21251989. <http://dx.doi.org/10.1101/2021.02.24.21251989>
- [72] Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, Scott R, Sconza R, Price J, Margaritis M, Bergstrom M, Spyer MJ, Miralhes PB, Grant P, Kirk S, Valerio C, Mangera Z, Prabhakar T, Moreno-Cuesta J, Arulkumaran N, Singer M, Shin GY, Sanchez E, Paraskevopoulou SM, Pillay D, McKendry RA, Mirfenderesky M, Houlihan CF, Nastouli E: Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. *Lancet Infect Dis* 2021.
- [73] Lyngse FP, Mølbak K, Skov RL, Christiansen LE, Mortensen LH, Albertsen M, Møller CH, Krause TG, Rasmussen M, Michaelsen TY, Voldstedlund M, Fonager J, Steenhard N, Kirkeby C: Increased Transmissibility of SARS-CoV-2 Lineage B.1.1.7 by Age and Viral Load: Evidence from Danish Households. medRxiv 2021:2021.04.16.21255459. <http://dx.doi.org/10.1101/2021.04.16.21255459>
- [74] Kidd M, Richter A, Best A, Cumley N, Mirza J, Percival B, Mayhew M, Megram O, Ashford F, White T, Moles-Garcia E, Crawford L, Bosworth A, Atabani SF, Plant T, McNally A: S-Variant SARS-CoV-2 Lineage B.1.1.7 Is Associated With Significantly Higher Viral Load in Samples Tested by TaqPath Polymerase Chain Reaction. *J Infect Dis* 2021, 223:1666-70.
- [75] Supasa P, Zhou D, Dejnirattisai W, Liu C, Mentzer AJ, Ginn HM, Zhao Y, Duyvesteyn HME, Nutalai R, Tuekprakhon A, Wang B, Paesen GC, Slon-Campos J, Lopez-Camacho C, Hallis B, Coombes N, Bewley KR, Charlton S, Walter TS, Barnes E, Dunachie SJ, Skelly D, Lumley SF, Baker N, Shaik I, Humphries HE, Godwin K, Gent N, Sienkiewicz A, Dold C, Levin R, Dong T, Pollard AJ, Knight JC, Klennerman P, Crook D, Lambe T, Clutterbuck E, Bibi S, Flaxman A, Bittaye M, Belij-Rammerstorfer S, Gilbert S, Hall DR, Williams MA, Paterson NG, James W, Carroll MW, Fry EE, Mongkolsapaya J, Ren J, Stuart DI, Screaton GR: Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. *Cell* 2021, 184:2201-11 e7.
- [76] Emary KRW, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, Blane B, Bonsall D, Cicconi P, Charlton S, Clutterbuck EA, Collins AM, Cox T, Darton TC, Dold C, Douglas AD, Duncan CJA, Ewer KJ, Flaxman AL, Faust SN, Ferreira DM, Feng S, Finn A, Folegatti PM, Fuskova M, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hallis B, Heath PT, Hay J, Hill HC, Jenkin D, Kerridge S, Lazarus R, Libri V, Lillie PJ, Ludden C, Marchevsky NG, Minassian AM, McGregor AC, Mujadidi YF, Phillips DJ, Plested E, Pollock KM, Robinson H, Smith A, Song R, Snape MD, Sutherland RK, Thomson EC, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Williams CJ, Hill AVS, Lambe T, Gilbert SC, Voysey M, Ramasamy MN, Pollard AJ, consortium C-GU, Project A, Oxford C-VTG: Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. *Lancet* 2021, 397:1351-62.
- [77] Collier DA, De Marco A, Ferreira I, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, Bianchi S, Tortorici MA, Bowen J, Culap K, Jaconi S, Cameroni E, Snell G, Pizzuto MS, Pellanda AF, Garzoni C, Riva A, Collaboration C-NBC-, Elmer A, Kingston N, Graves B, McCoy LE, Smith KGC, Bradley JR, Temperton N, Ceron-Gutierrez L, Barcenas-Morales G, Consortium C-GU, Harvey W, Virgin HW, Lanzavecchia A, Piccoli L, Doffinger R, Wills M, Veesler D, Corti D, Gupta RK: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature* 2021, 593:136-41.

- [78] Muik A, Wallisch AK, Sanger B, Swanson KA, Muhl J, Chen W, Cai H, Maurus D, Sarkar R, Tureci O, Dormitzer PR, Sahin U: Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. *Science* 2021, 371:1152-3.
- [79] Mahase E: Covid-19: Where are we on vaccines and variants? *BMJ* 2021, 372:n597.
- [80] Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, Ho DD: Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. *bioRxiv* 2021. <http://dx.doi.org/10.1101/2021.01.25.428137>
- [81] Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS: Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. *JAMA* 2021, 325:1896-8.
- [82] Wu K, Werner AP, Moliva JJ, Koch M, Choi A, Stewart-Jones GBE, Bennett H, Boyoglu-Barnum S, Shi W, Graham BS, Carfi A, Corbett KS, Seder RA, Edwards DK: mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. *bioRxiv* 2021:2021.01.25.427948. <http://dx.doi.org/10.1101/2021.01.25.427948>
- [83] Altmann DM, Boyton RJ, Beale R: Immunity to SARS-CoV-2 variants of concern. *Science* 2021, 371:1103-4.
- [84] Wise J: Covid-19: The E484K mutation and the risks it poses. *BMJ* 2021, 372:n359.
- [85] Dagpunar J: Interim estimates of increased transmissibility, growth rate, and reproduction number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom. *medRxiv* 2021. <http://dx.doi.org/10.1101/2021.06.03.21258293>

Figure Legends

Figure 1 Epidemiologic curve showing three waves of SARS-CoV-2 infections in Houston Methodist patients. Daily totals are shown as a +/- three-day moving average. The figure was generated with Tableau version 2020.3.4 (Tableau Software, LLC, Seattle, WA).

Figure 2 Cumulative increase in SARS-CoV-2 B.1.1.7, B.1.429, P.1 and P.2 variants and their distribution in metropolitan Houston. The time frame used is January 1, 2021 through May 31, 2021. The left column shows the cumulative increase in unique patients with each variant. The right column shows the geospatial distribution of these variants based on the home address zip code for each patient. Figures were generated with Tableau version 2020.3.4 (Tableau Software, LLC, Seattle, WA).

Figure 3 Cumulative increase in SARS-CoV-2 B.1.427, R.1, B.1.526 and B.1.525 variants and their distribution in metropolitan Houston. The time frame used is January 1, 2021 through May 31, 2021. The left column shows the cumulative increase in unique patients with each variant. The right column shows the geospatial distribution of these variants based on the home address zip code for each patient. Figures were generated with Tableau version 2020.3.4 (Tableau Software, LLC, Seattle, WA).

Figure 4 Cumulative increase in SARS-CoV-2 B.1.617.2, B.1.526.1, B.1.617.1 and B.1.351 variants and their distribution in metropolitan Houston. The time frame used is January 1, 2021 through May 31, 2021. The left column shows the cumulative increase in unique patients with

each variant. The right column shows the geospatial distribution of these variants based on the home address zip code for each patient. Figures were generated with Tableau version 2020.3.4 (Tableau Software, LLC, Seattle, WA).

Figure 5 Structural changes present in spike protein of the major SARS-CoV-2 variants identified in the study, including VOIs, VOCs, and variant R.1. S1-NTD, S1 domain-aminoterminal domain; S1-RBD, S1 domain-receptor binding domain; S1, S1 domain; S2, S2 domain. The figure is a modified version of one presented previously¹⁰, with permission from Elsevier.

Figure 6 Structural changes present in spike protein of B.1.617-family variants. Four subvariants of B.1.617.1 and 10 subvariants of B.1.617.2 were identified. For the purpose of clarity, each subvariant was given an upper-case letter designation. The subvariants are listed (top to bottom) based on their decreasing abundance in GISAID as of June 2, 2021. For example, B.1.617.1-A is the most common subvariant of B.1.617.1, and B.1.617.2-A is the most common subvariant of B.1.617.2. The number in parentheses below the subvariant designation denotes the number of patients with each subvariant identified in this study. Note that some annotation methods treat the E156G and del157-158 differently; we have used the GISAID annotation nomenclature. S1-NTD, S1 domain-aminoterminal domain; S1-RBD, S1 domain-receptor binding domain; S1, S1 domain; S2, S2 domain. The figure is a modified version of one presented previously¹⁰, with permission from Elsevier.

Figure 7 Cycle threshold (Ct) for every SARS-CoV-2 patient sample tested using the Abbott Alinity m (panels A-F) or Hologic Panther (panel G-L) assays as described in Materials and Methods. Data are presented as median with 95% Confidence Interval. Mann-Whitney test, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.

Figure 8 Number of COVID-19 vaccine breakthrough cases over time, by virus variant. The month of diagnosis and the infecting virus variant based on whole-genome sequencing are shown. A total of 207 vaccine breakthrough cases was identified in patient receiving either the Pfizer ($n = 181$; 87%) or Moderna ($n = 26$; 13%) vaccine.

Table 1. Summary of pertinent patient metadata for the 12,476 unique patients

	B.1.1.7 Variant	Other Variants	Total	Statistical Analysis
No. (%) with data	3276 (26.3%)	9200 (73.7%)	12476	
Patient Characteristics				
Median Age (Years)	49.9	53.7	52.5	P<0.0001 Mann-Whitney
Female	1693 (51.7%)	4880 (53.0%)	6573 (52.7%)	P=0.1854 Fisher's exact test
Male	1583 (48.3%)	4320 (47.0%)	5903 (47.3%)	
Ethnicity				
Caucasian	1304 (40.1%)	3720 (40.6%)	5024 (40.5%)	P<0.0001 Chi-square
Hispanic or Latino	945 (29.1%)	2720 (29.7%)	3665 (29.5%)	
Black	748 (23.0%)	1644 (18.0%)	2392 (19.3%)	
Asian	128 (3.9%)	549 (6.0%)	677 (5.5%)	
Native American	16 (0.5%)	28 (0.3%)	44 (0.4%)	
Hawaiian/Pacific Islander	3 (0.1%)	23 (0.3%)	26 (0.2%)	
Unavailable	107 (3.3%)	472 (5.2%)	579 (4.7%)	
BMI				
Median BMI	30.4	29.5	n=(11009)	P<0.0001 Mann-Whitney
<18.5	48 (1.5%)	140 (1.5%)	188 (1.5%)	P<0.0001 Chi-square
18.5-25	506 (15.4%)	1608 (17.5%)	2114 (16.9%)	
25-30	857 (26.2%)	2520 (27.4%)	3377 (27.1%)	
30-35	740 (22.6%)	1833 (19.9%)	2573 (20.6%)	
>=35	811 (24.8%)	1946 (21.2%)	2757 (22.1%)	
Unknown	314 (9.6%)	1153 (12.5%)	1467 (11.8%)	
Admission Data				
Admitted	1768 (54.0%)	4265 (46.4%)	6033 (48.4%)	P<0.0001 Fisher's exact test Odds Ratio: 1.357 (95% CI 1.252 to 1.469)
Not Admitted	1508 (46.0%)	4935 (53.6%)	6443 (51.6%)	
Median LOS (Days)	5.1	5.2	5.2	P=0.8917 Mann-Whitney
Max Respiratory Support				
ECMO	8 (0.5%)	17 (0.4%)	25 (0.4%)	P=0.0135 Chi-square
Mechanical Ventilation	150 (8.5%)	365 (8.6%)	515 (8.5%)	
Non-Invasive Ventilation	169 (9.6%)	433 (10.2%)	602 (10.0%)	
High Flow Oxygen	358 (20.2%)	696 (16.3%)	1054 (17.5%)	
Low Flow Oxygen	734 (41.5%)	1830 (42.9%)	2564 (42.5%)	
Room Air	349 (19.7%)	924 (21.7%)	1273 (21.1%)	
Mortality				
Alive	3132 (95.6%)	8760 (95.2%)	11892 (95.3%)	P=0.3862 Fisher's exact test Odds Ratio: 0.915 (95% CI 0.755 to 1.111)
Deceased	144 (4.4%)	440 (4.8%)	584 (4.7%)	
Median PCR Cycle Threshold				
Abbott Alinity	23.9 n=(1133)	26.8 n=(3344)	n=(4477)	P<0.0001 Mann-Whitney
Hologic Panther	25.0 n=(385)	26.2 n=(1574)	n=(1959)	P=0.0274 Mann-Whitney
Vaccine				
No vaccine	3023 (92.3%)	8715 (94.7%)	11738 (94.1%)	P<0.0001 Chi-square
>7 days past 1st Vaccine	127 (3.9%)	404 (4.4%)	531 (4.3%)	
>14 days past 2nd Vaccine	126 (3.8%)	81 (0.9%)	207 (1.7%)	


Data include 12476 unique patients with high-quality sequence results between January 1, 2021, and May 31, 2021.









CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay









Table 2. Summary of pertinent patient metadata for B.1.617.1/B.1.617.2 patients (excluding B.1.1.7 patients).

	B.1.617 Variants	Other Variants	Total	Statistical Analysis
No. (%) with data	22 (0.2%)	9178 (99.8%)	9200	
Ethnicity				
Asian	7 (33.3%)	542 (5.9%)	549 (6.0%)	P<0.001 Fisher's exact test (Asian vs non-Asian) Odds Ratio: 7.927 (95% CI 2.973 to 19.40)
Caucasian	8 (38.1%)	3712 (40.6%)	3720 (40.6%)	
Hispanic or Latino	3 (14.3%)	2717 (29.7%)	2720 (29.7%)	
Black	0 (0%)	1644 (18.0%)	1644 (18.0%)	
Native American	1 (4.8%)	27 (0.3%)	28 (0.3%)	
Hawaiian/Pacific Islander	1 (4.8%)	22 (0.2%)	23 (0.3%)	
Unavailable	1 (4.8%)	471 (5.2%)	472 (5.2%)	
Admission Data				
Admitted	17 (77.3%)	4248 (46.3%)	4265 (46.4%)	P=0.0045 Fisher's exact test Odds Ratio: 3.946 (95% CI 1.529 to 9.788)
Not Admitted	5 (22.7%)	4930 (53.7%)	4935 (53.6%)	
Median LOS (Days)	6.7	5.2		P=0.5388 Mann-Whitney
Highest level of care				
ICU	3 (17.6%)	639 (15.0%)	642 (15.1%)	P=0.5474 Mann-Whitney
IMU	1 (5.9%)	93 (2.2%)	94 (2.2%)	
Other Inpatient	13 (76.5%)	3516 (82.8%)	3529 (82.7%)	
Max Respiratory Support				
ECMO	0 (0%)	17 (0.4%)	17 (0.4%)	P>0.9999 Fisher's exact test (Room Air & Low Flow vs Other) Odds Ratio: 1.006 (95% CI 0.3803 to 2.647)
Mechanical Ventilation	3 (17.6%)	362 (8.5%)	365 (8.6%)	
Non-Invasive Ventilation	1 (5.9%)	432 (10.2%)	433 (10.2%)	
High Flow Oxygen	2 (11.8%)	694 (16.3%)	696 (16.3%)	
Low Flow Oxygen	8 (47.1%)	1822 (42.9%)	1830 (42.9%)	
Room Air	3 (17.6%)	921 (21.7%)	924 (21.7%)	
Mortality				
Alive	20 (90.9%)	8740 (95.2%)	8760 (95.2%)	P=0.2838 Fisher's exact test Odds Ratio TODO: 1.995 (95% CI 0.459 to 7.462)
Deceased	2 (9.1%)	438 (4.8%)	440 (4.8%)	



Data include 9200 unique patients with high-quality sequence results between January 1, 2021, and May 31, 2021.
CI: confidence interval; ICU: Intensive Care Unit; IMU: Intermediate Care Unit; ECMO: extracorporeal membrane oxygenation; LOS: length of stay











B.1.617.2
($n = 17$)





B.1.526.1
($n = 9$)





B.1.617.1
($n = 5$)














B.1.351
($n = 4$)







A**B****C****D****E****F****G****H****I****J****K****L**